ALBANY, N.Y., April 2, 2015 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) announced today that it has decided to close its Holywell,
U.K. facility following a consultation process with employee
representatives. The Holywell site provides chemical development
services and small- and large scale-manufacturing services of
active pharmaceutical ingredients (API) and intermediates.
"This was a difficult decision as it impacts team members who
have made valuable contributions to AMRI," said William S. Marth, AMRI President and Chief
Executive Officer. "We will work diligently to ensure the closing
of the Holywell facility goes as smoothly as possible for our
customers and employees."
AMRI will transition activities at the Holywell site to other
facilities within the AMRI network and plans to cease operations at
the site by the end of 2015. Closure of the site is expected to
affect approximately 62 positions.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids, and cytotoxic compounds.
Drug Product Manufacturing supports pre-clinical through commercial
scale production of complex liquid-filled and lyophilized
parenteral formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
About AMRI API Manufacturing
With demonstrated success
in large scale API Manufacturing, we offer the preeminence and
scale to support the chemical development and cGMP manufacture of
complex Active Pharmaceutical Ingredients (API). Our global
manufacturing footprint, which also includes manufacturing in
Europe and India, provides customers with access to
global markets and low-cost manufacturing of APIs or intermediates.
In addition, we have the skills and infrastructure to adequately
provide complex API research and development, analytical support
and support with global regulatory activities.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-to-close-holywell-uk-api-manufacturing-facility-300060559.html
SOURCE AMRI